Trial · NCT07908953
Prospective Evaluation of Recombinant Pbserum Plus® and Pbserum HA 2.0® in Aesthetic and Regenerative Bioremodeling
NCT07908953, Not applicable, Not yet recruiting, Antony Barbosa Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prospective Evaluation of Recombinant Pbserum Plus® and Pbserum HA 2.0® in Aesthetic and Regenerative Bioremodeling. Trials, record NCT07908953. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908953
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prospective Evaluation of Recombinant Pbserum Plus® and Pbserum HA 2.0® in Aesthetic and Regenerative Bioremodeling
- NCT number
- NCT07908953
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Antony Barbosa Institute
- Conditions
- Skin Laxity, Localized Adiposity, Cellulite, Tissue Fibrosis, Pathological Scarring
- Interventions
- Recombinant Hyaluronic Acid (pbserum HA 2.0®), pbserum Plus®
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Safety | From the intervention through Day 180 | Incidence, severity, duration, presumed causality, and clinical management of adverse events and treatment-related complications, including immediate, early, and late adverse events, local or systemic reactions, need for corrective intervention, and treatment discontinuation due to intolerance. |
| Primary | Change in Skin Elasticity Measured by Cutometry | Baseline and Day 180 | Change from baseline in skin biomechanical properties at the treated area, assessed by cutometry using standardized acquisition procedures. Cutometry will measure skin deformation and recoil parameters to evaluate changes in skin elasticity and laxity. Values recorded at each follow-up assessment will be compared with the corresponding baseline value. |
| Primary | Change From Baseline in Subcutaneous Fat Thickness Measured by Ultrasonography | Baseline and Day 90 | Change from baseline in subcutaneous fat thickness at the treated area, measured in millimeters by soft-tissue ultrasonography using a standardized acquisition protocol. The outcome will be calculated as the measurement at Day 180 minus the corresponding baseline measurement. Negative values indicate a reduction in subcutaneous fat thickness. |
| Primary | Change in Treated-Area Volume | Baseline and Day 90 | Change from baseline in the volume of the treated area, measured in cubic centimeters using Vectra® 3D imaging. The outcome will be calculated as the follow-up volume minus the baseline volume. Negative values indicate a reduction in treated-area volume. |
| Primary | Change From Baseline in Cellulite Severity Scale Score | Baseline and Day 180 | Change from baseline in cellulite severity assessed using the Cellulite Severity Scale. The total score is calculated from five clinical characteristics: number of depressions, depth of depressions, morphological appearance, skin laxity, and the Nürnberger-Müller classification grade. Higher scores indicate greater cellulite severity. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908953
GET https://conductscience.org/api/trials/v1/NCT07908953/registered